Myasthenia Gravis: Causes, Diagnosis, and Treatment
This paper examines myasthenia gravis (MG), a common autoimmune disorder characterized by fluctuating muscular weakness, through a comparative analysis of two key studies: Angelini (2011) and Romi, Gilhus, and Aarli (2005). The paper explores the disorder's autoimmune etiology, involving antibody attacks on acetylcholine receptors at the neuromuscular junction, and discusses the challenges of diagnosis, which can take one to two years due to symptom overlap with other conditions. It also reviews the generally favorable prognosis and the range of treatment options available, including AChE inhibitors, immunotherapy, corticosteroids, thymectomy, and plasmapheresis. The paper concludes with recommendations for further research into evidence-based treatment protocols and improved diagnostic methods.
- Introduction to Myasthenia Gravis: Overview of MG prevalence and key sources reviewed
- Causes and Pathophysiology: Autoimmune attacks on AChR at neuromuscular junction
- Diagnosis of Myasthenia Gravis: Diagnostic challenges and methods across MG subgroups
- Prognosis: Generally favorable outlook with room for improvement
- Treatment Options: Medication, immunotherapy, and surgical treatment approaches
- Conclusions and Future Research Directions: Summary of findings and gaps requiring further study
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper maintains a clear comparative structure throughout, systematically contrasting and reconciling findings from two distinct studies on each major topic (etiology, diagnosis, prognosis, treatment).
- It identifies points of agreement and disagreement between sources honestly, such as noting Angelini's emphasis on diagnostic difficulty versus Romi et al.'s more straightforward clinical framing.
- The final section moves beyond summary to propose concrete, justified directions for further research, demonstrating critical engagement with the literature.
Key academic technique demonstrated
The paper demonstrates effective comparative literature synthesis. Rather than summarizing each source in isolation, the author weaves both studies together thematically — addressing causes, diagnosis, prognosis, and treatment in turn — and explicitly signals where sources converge or diverge. This approach shows the reader how the two bodies of evidence relate to one another rather than simply reporting them side by side.
Structure breakdown
The paper opens with a brief introduction establishing the clinical significance of myasthenia gravis and the two key sources under review. It then proceeds thematically through four content sections — causes, diagnosis, prognosis, and treatment — before a combined conclusion and future research section. Each thematic section draws on both studies and evaluates their agreement or tension, making the structure both logical and analytically coherent.
Introduction to Myasthenia Gravis
Myasthenia gravis is one of the most common autoimmune disorders — a group of diseases brought about by the loss of tolerance to self-antigens. With an annual incidence of between 2 and 4 per million, it has attracted considerable research into its causes, diagnosis, prognosis, and treatments. Notable examples include the study by Romi, Gilhus, and Aarli (2005) on the clinical, immunological, and therapeutic advances of this disease, as well as the systematic review of its diagnosis and management by Angelini (2011).
Causes and Pathophysiology
Angelini (2011) defines myasthenia gravis as an autoimmune disorder caused by the body's immune attack on its own muscle endplate (p. 2). In this process, an antibody binds to AChR alpha subunits or MuSK and contributes to muscle weakness and abnormal neuromuscular transmission. Similarly, Romi, Gilhus, and Aarli (2005) state that the disorder results from autoimmune attacks on the body's own muscles. These researchers further note that it is characterized by unpredictable pathological weakness, with remissions or exacerbations affecting different skeletal muscle groups. Both studies agree that this pathological weakness is caused by antibodies targeting the AChR alpha subunit at the neuromuscular junction.
Diagnosis of Myasthenia Gravis
Myasthenia gravis is typically diagnosed based on patient history and characteristic clinical findings, and can be confirmed pharmacologically through specific testing (Romi, Gilhus, and Aarli, 2005). Angelini (2011) offers a contrasting perspective, arguing that the disorder is challenging to diagnose because of its fluctuating nature and symptoms that overlap with those of other conditions. That study concludes that the time to diagnosis is usually between one and two years, as patients are frequently misdiagnosed initially with anxiety or mood disorders.
Despite this disagreement, both studies agree that the disorder can be diagnosed through four main approaches: pharmacological testing, serological testing, electrophysiological testing, and imaging. The variation in diagnostic methods reflects differences in the disorder's subgroups and severity.
References
Angelini, C. (2011). Diagnosis and management of autoimmune myasthenia gravis. Clinical Drug Investigation, 31(1), 1–14.
Romi, F., Gilhus, N. E., & Aarli, J. A. (2005). Myasthenia gravis: Clinical, immunological, and therapeutic advances. Acta Neurologica Scandinavica, 111, 134–141.
Create your account
Always verify citation format against your institution’s current style guide requirements.